Ventria Bioscience

Last updated
Ventria Bioscience
Type Private company
Industry Biotechnology
Founded1993
Headquarters Fort Collins, CO
Area served
United States
ProductsBioscience Products
Website www.ventria.com

Ventria Bioscience is a biotech company with a focus on human nutrition and human therapeutics. The company was established in 1993 in Colorado. [1] The company's core technology is a genetically modified crop-based protein production system (also called a "pharming" system) called ExpressTec.

Contents

ExpressTec uses self-pollinating crops such as rice and barley to minimize the risk of gene flow normally associated with transgenic plants. Plant-produced proteins also offer advantages for cell culture and bioprocessing use because they replace animal derived components, which have become unpopular due to concerns about prion contamination.[ citation needed ]

Facilities

Ventria's corporate headquarters is in Denver, Colorado, with additional facilities in Kansas. On September 29, 2006, Kansas officials announced an agreement to bring Ventria’s new bioprocessing facility to Junction City, Kansas. Kansas Governor Kathleen Sebelius was very supportive of the agreement and was quoted as stating "I welcome Ventria Bioscience to Kansas and look forward to their contributions to the health of children worldwide." [2] The effort to attract Ventria to Kansas involved a number of players, including Governor Kathleen Sebelius, Secretary of Agriculture Adrian Polansky, The Kansas Department of Commerce, Junction City and Geary County, Kansas Technology Enterprise Corporation (KTEC), KansasBIO, Kansas State University, and Kansas Farm Bureau.

Markets and products

As of 2012 Ventria is developing six therapeutic products:

The company offers contract biomanufacturing services using its ExpressTec platform, and, through its subsidiary InVitria, sells a line of its proteins that it manufactures for the life sciences research market. [9]

The company is conducting research in the field of zoonotic disease, specifically in lyme disease and rabies, with a goal of developing vaccines and offers some its recombinant proteins to life sciences researchers under a program called BioShare. [10]

See also

Related Research Articles

<span class="mw-page-title-main">Genetic engineering</span> Manipulation of an organisms genome

Genetic engineering, also called genetic modification or genetic manipulation, is the modification and manipulation of an organism's genes using technology. It is a set of technologies used to change the genetic makeup of cells, including the transfer of genes within and across species boundaries to produce improved or novel organisms. New DNA is obtained by either isolating and copying the genetic material of interest using recombinant DNA methods or by artificially synthesising the DNA. A construct is usually created and used to insert this DNA into the host organism. The first recombinant DNA molecule was made by Paul Berg in 1972 by combining DNA from the monkey virus SV40 with the lambda virus. As well as inserting genes, the process can be used to remove, or "knock out", genes. The new DNA can be inserted randomly, or targeted to a specific part of the genome.

<span class="mw-page-title-main">Monoclonal antibody</span> Antibodies from clones of the same blood cell

A monoclonal antibody is an antibody produced from a cell line made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.

<span class="mw-page-title-main">Kathleen Sebelius</span> American businesswoman and politician (born 1948)

Kathleen Sebelius is an American businesswoman and politician who served as the 21st United States secretary of Health and Human Services from 2009 until 2014. As Secretary of Health and Human Services, Sebelius was instrumental in overseeing the implementation of the Affordable Care Act. Before becoming secretary, she served as the 44th governor of Kansas from 2003 to 2009, the second woman to hold that office. She is a member of the Democratic Party. Sebelius was the Democratic respondent to the 2008 State of the Union address and is chair-emerita of the Democratic Governors Association. She is CEO of Sebelius Resources LLC.

<span class="mw-page-title-main">Recombinant DNA</span> DNA molecules formed by human agency at a molecular level generating novel DNA sequences

Recombinant DNA (rDNA) molecules are DNA molecules formed by laboratory methods of genetic recombination that bring together genetic material from multiple sources, creating sequences that would not otherwise be found in the genome.

Pharming, a portmanteau of "farming" and "pharmaceutical", refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). Pharming is also known as molecular farming, molecular pharming or biopharming.

A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living medicines used in cell therapy. Biologics can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine.

Transcytosis is a type of transcellular transport in which various macromolecules are transported across the interior of a cell. Macromolecules are captured in vesicles on one side of the cell, drawn across the cell, and ejected on the other side. Examples of macromolecules transported include IgA, transferrin, and insulin. While transcytosis is most commonly observed in epithelial cells, the process is also present elsewhere. Blood capillaries are a well-known site for transcytosis, though it occurs in other cells, including neurons, osteoclasts and M cells of the intestine.

<span class="mw-page-title-main">History of biotechnology</span>

Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services. From its inception, biotechnology has maintained a close relationship with society. Although now most often associated with the development of drugs, historically biotechnology has been principally associated with food, addressing such issues as malnutrition and famine. The history of biotechnology begins with zymotechnology, which commenced with a focus on brewing techniques for beer. By World War I, however, zymotechnology would expand to tackle larger industrial issues, and the potential of industrial fermentation gave rise to biotechnology. However, both the single-cell protein and gasohol projects failed to progress due to varying issues including public resistance, a changing economic scene, and shifts in political power.

<span class="mw-page-title-main">Thermo Fisher Scientific</span> Provisioner of scientific consumables, equipment, and services

Thermo Fisher Scientific Inc. is an American supplier of scientific instrumentation, reagents and consumables, and software services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including: Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).

Biomolecular engineering is the application of engineering principles and practices to the purposeful manipulation of molecules of biological origin. Biomolecular engineers integrate knowledge of biological processes with the core knowledge of chemical engineering in order to focus on molecular level solutions to issues and problems in the life sciences related to the environment, agriculture, energy, industry, food production, biotechnology and medicine.

GeoVax is a clinical-stage biotechnology company initially established primarily to develop an effective and safe vaccine against many serious human diseases for which there are significant unmet medical needs. GeoVax’ novel development platform builds on the proven clinical and commercial success of the Modified Vaccinia Ankara (MVA) vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax technology approach uses recombinant DNA or recombinant viruses to produce virus-like particles (VLPs) in the person being vaccinated. In human clinical trials of the company’s HIV vaccines, GeoVax demonstrated that VLPs are safe and eliciting both strong and durable humoral and cellular immune response.

<span class="mw-page-title-main">Genetically modified rice</span>

Genetically modified rice are rice strains that have been genetically modified. Rice plants have been modified to increase micronutrients such as vitamin A, accelerate photosynthesis, tolerate herbicides, resist pests, increase grain size, generate nutrients, flavors or produce human proteins.

DARPins are genetically engineered antibody mimetic proteins typically exhibiting highly specific and high-affinity target protein binding. They are derived from natural ankyrin repeat proteins, one of the most common classes of binding proteins in nature, which are responsible for diverse functions such as cell signaling, regulation and structural integrity of the cell. DARPins consist of at least three, repeat motifs or modules, of which the most N- and the most C-terminal modules are referred to as "caps", since they shield the hydrophobic core of the protein. The number of internal modules is indicated as number while the caps are indicated with "N" or "C", respectively. The molecular mass of e.g. 14 or 18 kDa (kilodaltons) for four- (N2C) or five- (N3C) repeat DARPins is rather small for a biologic.

A chemically defined medium is a growth medium suitable for the in vitro cell culture of human or animal cells in which all of the chemical components are known. Standard cell culture media commonly consist of a basal medium supplemented with animal serum as a source of nutrients and other ill-defined factors. The technical disadvantages to using serum include its undefined nature, batch-to-batch variability in composition, and the risk of contamination.

<span class="mw-page-title-main">Moss bioreactor</span>

A moss bioreactor is a photobioreactor used for the cultivation and propagation of mosses. It is usually used in molecular farming for the production of recombinant protein using transgenic moss. In environmental science moss bioreactors are used to multiply peat mosses e.g. by the Mossclone consortium to monitor air pollution.

SynBio is a long-term project started in 2011 with the goal of creating innovative medicines, including what are known as Biobetters. This project is a collaborative effort of several Russian and international pharmaceutical companies. The largest private participant of SynBio is the Human Stem Cells Institute (HSCI), a leading Russian biotech company, and Rusnano is a key investor. The project is a significant example of international cooperation between researchers in Russia, England, and Germany. Special project company SynBio LLC is headquartered in Moscow.

GC Pharma [Green Cross Corporation] is a biopharmaceutical company headquartered in Yongin, South Korea.

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of February 2014, Repligen employed 116 people, about 50% of these based in Sweden.

Professor Peter Gray is a bioengineer who has played a key role in the development of modern industrial biotechnology in Australia. He was Professor and Head of Biotechnology at the University of New South Wales (UNSW), Sydney, from 1988 – 2003, and was the inaugural Director of the Australian Institute for Bioengineering and Nanotechnology (AIBN) at The University of Queensland in Brisbane, Australia from 2003 – 2015.

Synageva BioPharma Corp. was a publicly listed biopharmaceutical company headquartered in Lexington, Massachusetts dedicated to discovering, developing and delivering medicines for patients with rare diseases and high unmet medical needs. The company had manufacturing and laboratory locations in Lexington and Holden, Massachusetts, Bogart and Athens Georgia, as well as offices in a variety of locations around the world.

References

  1. Bloomberg BusinessWeek - Ventria Bioscience, Inc.
  2. "Kansas Bio" (PDF).
  3. Ventria VEN100 page
  4. Ventria VEN101 page
  5. Ventria VEN120 page
  6. Ventria VEN130 page
  7. Ventria VEN140 information on pipeline page
  8. Ventria VEN200 page
  9. InVitria Official Website
  10. "BioShare | Research Collaborations with Ventria Bioscience".